Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 237

1.

Association of a rare variant of the TNFSF13B gene with susceptibility to Rheumatoid Arthritis and Systemic Lupus Erythematosus.

González-Serna D, Ortiz-Fernández L, Vargas S, García A, Raya E, Fernández-Gutierrez B, López-Longo FJ, Balsa A, González-Álvaro I, Narvaez J, Gómez-Vaquero C, Sabio JM, García-Portales R, González-Escribano MF, Tolosa C, Carreira P, Kiemeney L, Coenen MJH, Witte T, Schneider M, González-Gay MÁ, Martín J.

Sci Rep. 2018 May 29;8(1):8195. doi: 10.1038/s41598-018-26573-4.

2.

Golimumab tapering strategy based on serum drug levels in patients with spondyloarthritis.

Redondo C, Martínez-Feito A, Plasencia-Rodríguez C, Navarro-Compán V, Nuño-Nuño L, Peiteado D, Villalba A, Jochems A, Pascual-Salcedo D, Balsa A.

Arthritis Rheumatol. 2018 May 7. doi: 10.1002/art.40542. [Epub ahead of print] No abstract available.

PMID:
29736972
3.

Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis.

Lopez-Rodriguez R, Perez-Pampin E, Marquez A, Blanco FJ, Joven B, Carreira P, Ferrer MA, Caliz R, Valor L, Narvaez J, Cañete JD, Ordoñez MDC, Manrique-Arija S, Vasilopoulos Y, Balsa A, Pascual-Salcedo D, Moreno-Ramos MJ, Alegre-Sancho JJ, Navarro-Sarabia F, Moreira V, Garcia-Portales R, Raya E, Magro-Checa C, Martin J, Gomez-Reino JJ, Gonzalez A.

PLoS One. 2018 May 7;13(5):e0196793. doi: 10.1371/journal.pone.0196793. eCollection 2018.

4.

Takotsubo Cardiomyopathy Associated with Levothyroxine Over-replacement.

Balsa AM, Ferreira AR, Alves M, Guimarães J.

Eur Endocrinol. 2017 Apr;13(1):30-32. doi: 10.17925/EE.2017.13.01.30. Epub 2017 Apr 3.

5.

Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review.

Martín-López M, Carmona L, Balsa A, Calvo-Alén J, Sanmartí R, Tornero J, Rosas J.

Rheumatol Int. 2018 Jun;38(6):975-983. doi: 10.1007/s00296-018-4022-4. Epub 2018 Apr 3. Review.

PMID:
29616303
6.

Lipid Profile in Relation to Glycemic Control in Type 1 Diabetes Children and Adolescents in Bangladesh.

Zabeen B, Balsa AM, Islam N, Parveen M, Nahar J, Azad K.

Indian J Endocrinol Metab. 2018 Jan-Feb;22(1):89-92. doi: 10.4103/ijem.IJEM_217_17.

7.

The comparative immunogenicity of biologic therapy and its clinical relevance in psoriatic arthritis: a systematic review of the literature.

Balsa A, Lula S, Marshall L, Szczypa P, Aikman L.

Expert Opin Biol Ther. 2018 May;18(5):575-584. doi: 10.1080/14712598.2018.1450385. Epub 2018 Mar 20.

PMID:
29533116
8.

Differential blood cellular profile in patients with moderate-to-severe psoriasis treated with classical systemic therapies: a step forward in personalized medicine.

Hernández-Breijo B, Jurado T, Rodríguez-Martín E, Martínez-Feito A, Plasencia-Rodríguez C, Balsa A, Alonso-Pacheco ML, Villar LM, Herranz-Pinto P, Pascual-Salcedo D.

Br J Dermatol. 2018 Mar 11. doi: 10.1111/bjd.16537. [Epub ahead of print] No abstract available.

PMID:
29526036
9.

Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.

Balsa A, Sanmarti R, Rosas J, Martin V, Cabez A, Gómez S, Montoro M.

Rheumatology (Oxford). 2018 Apr 1;57(4):688-693. doi: 10.1093/rheumatology/kex474.

PMID:
29365183
10.

Adalimumab concentration-based tapering strategy: as good as the recommended dosage.

Mulleman D, Balsa A.

Ann Rheum Dis. 2018 Apr;77(4):473-475. doi: 10.1136/annrheumdis-2017-212376. Epub 2018 Jan 6. No abstract available.

11.

REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients.

González-Álvaro I, Blasco AJ, Lázaro P, Sánchez-Piedra C, Almodovar R, Bachiller-Corral J, Balsa A, Caliz R, Candelas G, Fernández-Carballido C, García-Aparicio A, García-Magallón B, García-Vicuña R, Gómez-Centeno A, Ortiz AM, Sanmartí R, Sanz J, Tejera B.

Heliyon. 2017 Nov 14;3(11):e00452. doi: 10.1016/j.heliyon.2017.e00452. eCollection 2017 Nov.

12.

Use of Immunomodulatory Drugs at a Uveitis Clinic.

Millán-Longo C, Peiteado D, Schlincker A, Hidalgo V, Pieren A, Balsa A, de Miguel E.

Reumatol Clin. 2017 Nov 10. pii: S1699-258X(17)30246-2. doi: 10.1016/j.reuma.2017.09.008. [Epub ahead of print] English, Spanish.

13.

Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review.

Navarro-Compán V, Plasencia-Rodríguez C, de Miguel E, Diaz Del Campo P, Balsa A, Gratacós J.

RMD Open. 2017 Oct 10;3(2):e000524. doi: 10.1136/rmdopen-2017-000524. eCollection 2017.

14.

Optimal concentration range of golimumab in patients with axial spondyloarthritis.

Martínez-Feito A, Plasencia-Rodriguez C, Navarro-Compán V, Jurado T, Kneepkens EL, Wolbink GJ, Martín S, Ruiz Del Agua A, Navarro R, Mezcua A, Jochems A, Peiteado D, Bonilla MG, Balsa A, Pascual-Salcedo D.

Clin Exp Rheumatol. 2018 Jan-Feb;36(1):110-114. Epub 2017 Sep 15.

PMID:
28980904
15.

Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients.

Regueiro C, Nuño L, Ortiz AM, Peiteado D, Villalba A, Pascual-Salcedo D, Martínez-Feito A, González-Alvaro I, Balsa A, González A.

Sci Rep. 2017 Sep 20;7(1):12023. doi: 10.1038/s41598-017-09657-5.

16.

Prevalence of Comorbidities in Rheumatoid Arthritis and Evaluation of Their Monitoring in Clinical Practice: The Spanish Cohort of the COMORA Study.

Balsa A, Lojo-Oliveira L, Alperi-López M, García-Manrique M, Ordóñez-Cañizares C, Pérez L, Ruiz-Esquide V, Corrales A, Narváez J, Rey-Rey J, Rodríguez-Lozano C, Ojeda S, Muñoz-Fernández S, Nolla JM, García-Torrón J, Gamero F, García-Vicuña R, Hernández-Cruz B, Campos J, Rosas J, García-Llorente JF, Gómez-Centeno A, Cáliz R, Sanmartí R, Bermúdez A, Abasolo-Alcázar L, Fernández-Nebro A, Rodríguez-Rodríguez L, Marras C, González-Gay MÁ, Hmamouchi I, Martín-Mola E.

Reumatol Clin. 2017 Jul 12. pii: S1699-258X(17)30134-1. doi: 10.1016/j.reuma.2017.06.002. [Epub ahead of print] English, Spanish.

17.

Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis.

Medina F, Plasencia C, Goupille P, Ternant D, Balsa A, Mulleman D.

Ther Drug Monit. 2017 Aug;39(4):364-369. doi: 10.1097/FTD.0000000000000421. Review.

PMID:
28700520
18.

Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.

Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.

BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8. Review.

19.

Exploring the remission concept in rheumatoid arthritis with patients and rheumatologists: time for a new approach?

Acebes C, Andreu JL, Balsa A, Batlle E, de Toro-Santos J, García Llorente F, Hernández MV, Fernández-Gutiérrez B, Hidalgo-Calleja C, Mayordomo L, Naredo E, Narváez FJ, Ortiz AM, Pablos JL, Pérez-Sandoval T, Rodríguez-Lozano C, Sánchez-Pernaute O, Usón J, Negrón JB, Loza E, Carmona L, Gómez Castro S, Montoro Alvarez M.

Clin Exp Rheumatol. 2017 Sep-Oct;35(5):816-822. Epub 2017 May 8.

PMID:
28516881
20.

Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.

Reinisch W, Jahnsen J, Schreiber S, Danese S, Panés J, Balsa A, Park W, Kim J, Lee JU, Yoo DH.

BioDrugs. 2017 Jun;31(3):223-237. doi: 10.1007/s40259-017-0219-4.

21.

Evaluation of Toll-like-receptor gene family variants as prognostic biomarkers in rheumatoid arthritis.

Torices S, Alvarez-Rodríguez L, Varela I, Muñoz P, Balsa A, López-Hoyos M, Martinez-Taboada V, Fernández-Luna JL.

Immunol Lett. 2017 Jul;187:35-40. doi: 10.1016/j.imlet.2017.04.011. Epub 2017 May 7.

PMID:
28495399
22.

Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Spondyloarthritis.

Medina F, Plasencia C, Goupille P, Paintaud G, Balsa A, Mulleman D.

Ther Drug Monit. 2017 Aug;39(4):360-363. doi: 10.1097/FTD.0000000000000400. Review.

PMID:
28379895
23.

Influence of route of administration/drug formulation and other factors on adherence to treatment in rheumatoid arthritis (pain related) and dyslipidemia (non-pain related).

Fautrel B, Balsa A, Van Riel P, Casillas M, Capron JP, Cueille C, de la Torre I.

Curr Med Res Opin. 2017 Jul;33(7):1231-1246. doi: 10.1080/03007995.2017.1313209. Epub 2017 Apr 28. Review.

PMID:
28358217
24.

Ultrasound sensitivity to changes in gout: a longitudinal study after two years of treatment.

Peiteado D, Villalba A, Martín-Mola E, Balsa A, De Miguel E.

Clin Exp Rheumatol. 2017 Sep-Oct;35(5):746-751. Epub 2017 Mar 3.

PMID:
28281462
25.

Influence of coronary artery disease and subclinical atherosclerosis related polymorphisms on the risk of atherosclerosis in rheumatoid arthritis.

López-Mejías R, Corrales A, Vicente E, Robustillo-Villarino M, González-Juanatey C, Llorca J, Genre F, Remuzgo-Martínez S, Dierssen-Sotos T, Miranda-Filloy JA, Huaranga MA, Pina T, Blanco R, Alegre-Sancho JJ, Raya E, Mijares V, Ubilla B, Ferraz-Amaro I, Gómez-Vaquero C, Balsa A, López-Longo FJ, Carreira P, González-Álvaro I, Ocejo-Vinyals JG, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Castañeda S, Martín J, González-Gay MA.

Sci Rep. 2017 Jan 6;7:40303. doi: 10.1038/srep40303.

26.

[Evaluation of Uruguay's antismoking campaign: progress and challenges at ten years].

Triunfo P, Harris J, Balsa A.

Rev Panam Salud Publica. 2016 Oct;40(4):256-262. Spanish.

27.

Exposures to Particulate Matter from the Eruptions of the Puyehue Volcano and Birth Outcomes in Montevideo, Uruguay.

Balsa AI, Caffera M, Bloomfield J.

Environ Health Perspect. 2016 Nov;124(11):1816-1822. Epub 2016 May 6.

28.

A functional variant of TLR10 modifies the activity of NFkB and may help predict a worse prognosis in patients with rheumatoid arthritis.

Torices S, Julia A, Muñoz P, Varela I, Balsa A, Marsal S, Fernández-Nebro A, Blanco F, López-Hoyos M, Martinez-Taboada V, Fernández-Luna JL.

Arthritis Res Ther. 2016 Oct 4;18(1):221.

29.

Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis.

López-Mejías R, Genre F, Remuzgo-Martínez S, González-Juanatey C, Robustillo-Villarino M, Llorca J, Corrales A, Vicente E, Miranda-Filloy JA, Magro C, Tejera-Segura B, Ramírez Huaranga MA, Pina T, Blanco R, Alegre-Sancho JJ, Raya E, Mijares V, Ubilla B, Mínguez Sánchez MD, Gómez-Vaquero C, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, González-Álvaro I, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Ferraz-Amaro I, Castañeda S, Martín J, González-Gay MA.

Sci Rep. 2016 Aug 18;6:31979. doi: 10.1038/srep31979.

30.

Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study.

Kneepkens EL, van den Oever I, Plasencia CH, Pascual-Salcedo D, de Vries A, Hart M, Nurmohamed MT, Balsa A, Rispens T, Wolbink G.

Scand J Rheumatol. 2017 Mar;46(2):87-94. doi: 10.1080/03009742.2016.1183039. Epub 2016 Jul 20.

PMID:
27440258
31.

Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.

Martin-Mola E, Balsa A, García-Vicuna R, Gómez-Reino J, González-Gay MA, Sanmartí R, Loza E.

Rheumatol Int. 2016 Aug;36(8):1043-63. doi: 10.1007/s00296-016-3506-3. Epub 2016 Jun 6. Review.

PMID:
27271502
32.

Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity.

Plasencia C, Wolbink G, Krieckaert CL, Kneepkens EL, Turk S, Jurado T, Martínez-Feito A, Navarro-Compán V, Bonilla G, Villalba A, Peiteado D, Nuño L, Martín-Mola E, Nurmohamed MT, van der Kleij D, Rispens T, Pascual-Salcedo D, Balsa A.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4):655-62. Epub 2016 May 19.

PMID:
27214767
33.

A combined large-scale meta-analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus.

Márquez A, Vidal-Bralo L, Rodríguez-Rodríguez L, González-Gay MA, Balsa A, González-Álvaro I, Carreira P, Ortego-Centeno N, Ayala-Gutiérrez MM, García-Hernández FJ, González-Escribano MF, Sabio JM, Tolosa C, Suárez A, González A, Padyukov L, Worthington J, Vyse T, Alarcón-Riquelme ME, Martín J.

Ann Rheum Dis. 2017 Jan;76(1):286-294. doi: 10.1136/annrheumdis-2016-209436. Epub 2016 May 18.

PMID:
27193031
34.

Safety of antitumour necrosis factor treatments in chronic rheumatic diseases: therapy discontinuations related to side effects.

Varela H, Villamañán E, Plasencia C, Romero JA, Ruano M, Balsa A, Herrero A.

J Clin Pharm Ther. 2016 Jun;41(3):306-9. doi: 10.1111/jcpt.12393.

PMID:
27191537
35.

Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies.

López-Isac E, Martín JE, Assassi S, Simeón CP, Carreira P, Ortego-Centeno N, Freire M, Beltrán E, Narváez J, Alegre-Sancho JJ; Spanish Scleroderma Group, Fernández-Gutiérrez B, Balsa A, Ortiz AM, González-Gay MA, Beretta L, Santaniello A, Bellocchi C, Lunardi C, Moroncini G, Gabrielli A, Witte T, Hunzelmann N, Distler JH, Riekemasten G, van der Helm-van Mil AH, de Vries-Bouwstra J, Magro-Checa C, Voskuyl AE, Vonk MC, Molberg Ø, Merriman T, Hesselstrand R, Nordin A, Padyukov L, Herrick A, Eyre S, Koeleman BP, Denton CP, Fonseca C, Radstake TR, Worthington J, Mayes MD, Martín J.

Arthritis Rheumatol. 2016 Sep;68(9):2338-44. doi: 10.1002/art.39730.

36.

Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review.

Navarro-Compán V, Plasencia-Rodríguez C, de Miguel E, Balsa A, Martín-Mola E, Seoane-Mato D, Cañete JD.

Rheumatology (Oxford). 2016 Jul;55(7):1188-94. doi: 10.1093/rheumatology/kew033. Epub 2016 Mar 21. Review.

PMID:
26998860
37.

Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.

Ruiz-Argüello MB, Maguregui A, Ruiz Del Agua A, Pascual-Salcedo D, Martínez-Feito A, Jurado T, Plasencia C, Balsa A, Llinares-Tello F, Rosas J, Torres N, Martínez A, Nagore D.

Ann Rheum Dis. 2016 Sep;75(9):1693-6. doi: 10.1136/annrheumdis-2015-208684. Epub 2016 Mar 10.

PMID:
26965981
38.

Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required.

Moots RJ, Balsa A, Wolbink G.

Ann Rheum Dis. 2016 May;75(5):e24. doi: 10.1136/annrheumdis-2016-209178. Epub 2016 Feb 4. No abstract available.

PMID:
26847822
39.

PTGER4 gene variant rs76523431 is a candidate risk factor for radiological joint damage in rheumatoid arthritis patients: a genetic study of six cohorts.

Rodriguez-Rodriguez L, Ivorra-Cortes J, Carmona FD, Martín J, Balsa A, van Steenbergen HW, van der Helm-van Mil AH, González-Álvaro I, Fernandez-Gutiérrez B.

Arthritis Res Ther. 2015 Nov 5;17:306. doi: 10.1186/s13075-015-0830-z.

40.

A Truncated Variant of ASCC1, a Novel Inhibitor of NF-κB, Is Associated with Disease Severity in Patients with Rheumatoid Arthritis.

Torices S, Alvarez-Rodríguez L, Grande L, Varela I, Muñoz P, Pascual D, Balsa A, López-Hoyos M, Martinez-Taboada V, Fernández-Luna JL.

J Immunol. 2015 Dec 1;195(11):5415-20. doi: 10.4049/jimmunol.1501532. Epub 2015 Oct 26.

41.

Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions.

Plasencia C, Jurado T, Villalba A, Peitedado D, Casla MT, Nuño L, Bonilla MG, Martínez-Feito A, Martín-Mola E, Pascual-Salcedo D, Balsa A.

Front Med (Lausanne). 2015 Oct 8;2:71. doi: 10.3389/fmed.2015.00071. eCollection 2015.

42.

Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity.

Plasencia C, Kneepkens EL, Wolbink G, Krieckaert CL, Turk S, Navarro-Compán V, L'Ami M, Nurmohamed MT, van der Horst-Bruinsma I, Jurado T, Diego C, Bonilla G, Villalba A, Peiteado D, Nuño L, van der Kleij D, Rispens T, Martín-Mola E, Balsa A, Pascual-Salcedo D.

J Rheumatol. 2015 Sep;42(9):1638-46. doi: 10.3899/jrheum.141128. Epub 2015 Jul 15.

PMID:
26178279
43.

2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis.

Sanmartí R, García-Rodríguez S, Álvaro-Gracia JM, Andreu JL, Balsa A, Cáliz R, Fernández-Nebro A, Ferraz-Amaro I, Gómez-Reino JJ, González-Álvaro I, Martín-Mola E, Martínez-Taboada VM, Ortiz AM, Tornero J, Marsal S, Moreno-Muelas JV.

Reumatol Clin. 2015 Sep-Oct;11(5):279-94. doi: 10.1016/j.reuma.2015.05.001. Epub 2015 Jun 6. English, Spanish.

44.

Tobacco control campaign in Uruguay: Impact on smoking cessation during pregnancy and birth weight.

Harris JE, Balsa AI, Triunfo P.

J Health Econ. 2015 Jul;42:186-96. doi: 10.1016/j.jhealeco.2015.04.002. Epub 2015 Apr 29.

PMID:
25985121
45.

Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis.

Ferreiro-Iglesias A, Montes A, Perez-Pampin E, Cañete JD, Raya E, Magro-Checa C, Vasilopoulos Y, Sarafidou T, Caliz R, Ferrer MA, Joven B, Carreira P, Balsa A, Pascual-Salcedo D, Blanco FJ, Moreno-Ramos MJ, Fernández-Nebro A, Ordóñez MC, Alegre-Sancho JJ, Narváez J, Navarro-Sarabia F, Moreira V, Valor L, García-Portales R, Marquez A, Martin J, Gómez-Reino JJ, Gonzalez A.

Pharmacogenomics J. 2016 Apr;16(2):137-40. doi: 10.1038/tpj.2015.29. Epub 2015 Apr 21.

PMID:
25896535
46.

Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study.

Montes A, Perez-Pampin E, Navarro-Sarabia F, Moreira V, de la Serna AR, Magallares B, Vasilopoulos Y, Sarafidou T, Fernández-Nebro A, Ordóñez Mdel C, Narváez J, Cañete JD, Marquez A, Pascual-Salcedo D, Joven B, Carreira P, Moreno-Ramos MJ, Caliz R, Ferrer MA, Garcia-Portales R, Blanco FJ, Magro C, Raya E, Valor L, Alegre-Sancho JJ, Balsa A, Martin J, Plant D, Isaacs J, Morgan AW, Barton A, Wilson AG; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Gómez-Reino JJ, Gonzalez A.

Arthritis Res Ther. 2015 Mar 18;17:63. doi: 10.1186/s13075-015-0571-z.

47.

Lack of association between JAK3 gene polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis.

García-Bermúdez M, López-Mejías R, Genre F, Castañeda S, Corrales A, Llorca J, González-Juanatey C, Ubilla B, Miranda-Filloy JA, Pina T, Gómez-Vaquero C, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, Blanco R, Martín J, González-Gay MA.

Biomed Res Int. 2015;2015:318364. doi: 10.1155/2015/318364. Epub 2015 Mar 1.

48.

Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study.

Balsa A, Tovar Beltrán JV, Cáliz Cáliz R, Mateo Bernardo I, García-Vicuña R, Rodríguez-Gómez M, Belmonte Serrano MA, Marras C, Loza Cortina E, Pérez-Pampin E, Vila V.

Rheumatol Int. 2015 Sep;35(9):1525-34. doi: 10.1007/s00296-015-3237-x. Epub 2015 Mar 13.

PMID:
25773655
49.

Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis.

Loza E, Lajas C, Andreu JL, Balsa A, González-Álvaro I, Illera O, Jover JÁ, Mateo I, Orte J, Rivera J, Rodríguez Heredia JM, Romero F, Martínez-López JA, Ortiz AM, Toledano E, Villaverde V, Carmona L, Castañeda S.

Rheumatol Int. 2015 Mar;35(3):445-58. doi: 10.1007/s00296-014-3196-7. Epub 2014 Dec 28. Review.

PMID:
25543267
50.

Constitutively altered frequencies of circulating follicullar helper T cell counterparts and their subsets in rheumatoid arthritis.

Arroyo-Villa I, Bautista-Caro MB, Balsa A, Aguado-Acín P, Bonilla-Hernán MG, Plasencia C, Villalba A, Nuño L, Puig-Kröger A, Martín-Mola E, Miranda-Carús ME.

Arthritis Res Ther. 2014 Dec 5;16(6):500. doi: 10.1186/s13075-014-0500-6.

Supplemental Content

Support Center